Analysts Set $24.00 Target Price for Akcea Therapeutics, Inc. (AKCA)

Shares of Akcea Therapeutics, Inc. (NASDAQ:AKCA) have received an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Brokers have set a one year consensus price objective of $24.00 for the company, according to Zacks. Zacks has also assigned Akcea Therapeutics an industry rank of 110 out of 265 based on the ratings given to related companies.

A number of analysts recently commented on AKCA shares. Zacks Investment Research lowered Akcea Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cowen and Company reaffirmed a “buy” rating on shares of Akcea Therapeutics in a research report on Tuesday, October 31st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 target price (up from $19.00) on shares of Akcea Therapeutics in a research report on Tuesday, November 7th. Wells Fargo & Company started coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued an “outperform” rating and a $27.00 target price for the company. Finally, BMO Capital Markets started coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued an “outperform” rating and a $25.00 target price for the company.

A number of institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new stake in Akcea Therapeutics in the 3rd quarter valued at about $269,000. Granahan Investment Management Inc. MA bought a new stake in Akcea Therapeutics during the 3rd quarter worth approximately $8,528,000. California State Teachers Retirement System bought a new stake in Akcea Therapeutics during the 3rd quarter worth approximately $672,000. OxFORD Asset Management LLP bought a new stake in Akcea Therapeutics during the 3rd quarter worth approximately $6,872,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in Akcea Therapeutics during the 3rd quarter worth approximately $1,654,000. 19.15% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3050040/analysts-set-24-00-target-price-for-akcea-therapeutics-inc-akca.html.

Shares of Akcea Therapeutics (NASDAQ AKCA) traded up $0.26 during trading on Friday, reaching $18.39. The company had a trading volume of 112,500 shares, compared to its average volume of 418,963. Akcea Therapeutics has a twelve month low of $8.10 and a twelve month high of $31.23.

About Akcea Therapeutics

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Get a free copy of the Zacks research report on Akcea Therapeutics (AKCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.